Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a significant decline in short interest in May. As of May 29th, there was short interest totaling 20,834 shares, a decline of 35.5% from the May 14th total of 32,290 shares. Based on an average daily volume of 14,468 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.7% of the shares of the stock are sold short.

Exicure Price Performance

NASDAQ:XCUR opened at $2.17 on Wednesday. The business has a 50 day moving average of $3.27 and a 200 day moving average of $4.33. The company has a market capitalization of $13.82 million, a price-to-earnings ratio of -1.40 and a beta of 3.53. Exicure has a 1-year low of $1.71 and a 1-year high of $9.50.

Exicure (NASDAQ:XCUR) last released its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.